KGK SCIENCE INC. ANNOUNCES APPOINTMENTS OF STEPHEN HOLMES TO CFO &COO AND ASHLEY TEN HAAF TO DIRECTOR OF CLINICAL OPERATIONS
London, Ontario, September 10, 2018 – Najla Guthrie, President & CEO, of KGK Science Inc. (“KGK” or the “Company“) is pleased to announce that Stephen Holmes has been elevated to the dual role of Chief Financial Officer and Chief Operating Officer effective September 10, 2018. Additionally KGK would like to announce the promotion of Ashley ten Haaf to Director of Clinical Operations.
Stephen Holmes, ACA, joined KGK in March of 2018 as Vice President of Finance. Stephen brings significant financial and operational experience to KGK, having held leadership positions at various multinational corporations as well as medium sized enterprises, including the past role of CFO of a publicly traded Canadian company. Stephen earned his Bachelor of Administrative and Commercial Studies at the University of Western Ontario and has been a Chartered Accountant with the Institute of Chartered Accountants in Ireland since 2008.
Ashley ten Haaf previously held the position of Clinic Manager with KGK joining from a previous role as Clinical Project Manager at an innovative biopharmaceutical company. Ashley has over 15 years of experience in the clinical trials field, spanning multiple therapeutic areas, in every phase of development. Ashley has actively participated in the facilitation of over 100 pharmaceutical research trials as both Clinical Project Manager and Clinical Research Manager. Ashley earned her Bachelor’s of Science from the University of Waterloo and earned her Graduate certificate in Clinical Research from Western University. In 2012 Ashley obtained her CCRP designation and most recently obtained a certificate in Project Management from Western University.
Najla Guthrie, President & CEO commented: “On behalf of our leadership team and staff at KGK I would like to congratulate both Stephen and Ashley on their promotions to their respective positions. The skillset and experiences Stephen has brought to KGK can now be fully utilized in his dual roles of CFO and COO by guiding KGK on our growth trajectory. Stephen played a vital role in the successful acquisition of KGK by Auxly Cannabis Group in August. The Board of Directors at KGK and I look forward to continuing to work very closely with Stephen on all of our projects and ambitions moving into 2019.
Ashley has been an invaluable addition to our clinical operations allowing KGK to grow in scale and continue the clinical excellence we have been known for achieving over the past 21 years. Her experience in clinical trial management along with a dedication to quality research allows KGK to continue to excel in both our nutraceutical and pharmaceutical services.
These promotions signal both the clinical excellence we strive to achieve every day along with the proper mechanisms for financial growth as a company within the Auxly Cannabis Group.”
About KGK Science Inc
KGK Science is the leading contract research organization offering clinical trial services and regulatory consulting for the cannabis, dietary supplement, functional food, beverage, ingredient and cosmetic industry. For over 21 years, KGK Science has been designing and conducting clinical trials to support clients with product development, claims substantiation and product marketing. Along with offering a full suite of services that includes research strategy, regulatory support, market research, clinical trials and clinical trial management, KGK Science operates a clinical trial unit with experience in over 250 completed clinical trials in Canada, North America and Europe. KGK Science maintains an active database in Southwestern Ontario of over 15,000 participants. KGK Science’s major areas of expertise include, but are not limited to: digestive health, cognition, sport nutrition/performance, weight management, skin and hair, bioavailability, cardiovascular health, infant nutrition and immune health.
Follow up on Twitter @KGKScience
Media Enquiries (only):
For media enquiries or to set up an interview please contact:
Matthew Pizzuti, B2B Marketing Manager